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9.1. Overview of the enterohepatic circulation of bile acids 
 
Bile acids are amphipathic physiological detergents that play essential roles in promoting 
absorption, excretion, and transport of cholesterol, lipids, lipophilic nutrients, and other 
hydrophobic compounds in the liver and the intestine [1]. The two primary bile acids in 
humans are cholic acid (CA) and chenodeoxycholic acid (CDCA). In the intestinal bacterial 
flora these can be converted to secondary bile acids, deoxycholic acid (DCA) and lithocholic 
acid (LCA), respectively.  
Bile acids are synthesized from cholesterol in the liver and stored in the gall bladder, 
from which they are postprandially released into the small intestine. From the small intestine 
the bile acids are recycled back to the liver via portal blood. A bile acid molecule may shuttle 
up to a dozen times between the liver and the intestine during one day, each time crossing the 
membrane domains of hepatocytes and enterocytes. This enterohepatic circulation of bile 
acids is highly efficient in healthy human individuals: less than 10 % of the total bile acid 
pool escapes ileal reabsorption, and thus enters the colon. In the colon, secondary bile acids 
are formed, which may be either passively absorbed into colonocytes, or lost through fecal 
excretion. This small loss into feces is compensated for by hepatic de novo synthesis of bile 
acids from cholesterol, catalyzed by cascades of cytochrome P450 (CYP) enzymes located in 
endoplasmic reticulum, in mitochondria, or in cytosol [2]. Thus, conversion of cholesterol 
into bile acids also provides an important route for elimination of cholesterol from the human 
body. 
Disruption of the biliary secretion of bile acids may result in cholestasis, where 
intrahepatic and systemic accumulation of bile acids causes cytotoxicity. In the liver this may 
eventually progress to fibrosis and cirrhosis.  
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9.2.The chief transporters in the enterohepatic circulation of bile acids 
 
Enterohepatic circulation of bile acids is mediated by specific transporters, most of which are 
integral plasma membrane proteins, and are expressed in hepatocytes and enterocytes in a 
polarized manner [3]. The chief transporters involved in bile acid cycling and bile formation 
are presented in Figure 9-1, and discussed in more detail below. 
Following their synthesis, bile acids are excreted from hepatocytes into bile canaliculi. 
This represents a major driving force for generation of bile flow and is a rate-limiting step in 
overall bile acid transport. The efflux of monovalent bile acids from hepatocytes occurs 
mainly via the canalicular bile salt export pump (BSEP, ABCB11), which belongs to the 
superfamily of ATP-binding cassette (ABC) transporters [4]. The ABC transporters couple 
the energy released from ATP hydrolysis to their transport activity [5]. Most eukaryotic ABC 
proteins share several evolutionarily conserved domains, and typically contain two 
hydrophobic transmembrane domains, each of which spans the membrane six times. While 
BSEP is responsible for the efflux of monovalent bile acids from hepatocytes into bile, the 
multidrug resistance-associated protein 2 (MRP2, ABCC2) exports divalent and sulphated 
and/or glucuronidated bile acids, as well as other conjugated anions such as chemotherapeutic 
agents and antibiotics, into bile [6]. MRP2 is also a member of the ABC transporter family 
that is located at the canalicular membrane of hepatocytes. 
In addition to BSEP and MRP2, there are other transporters localized at the canalicular 
membrane of hepatocytes that are involved in bile formation. Whereas bile acids are the most 
prominent (60-70%) solid component of bile, hepatic bile also contains phospholipids, 
notably phosphatidylcholine, and cholesterol. Phospholipids are translocated from the inner to 
 4 
the outer leaflet of the canalicular membranes of hepatocytes by yet another ABC transporter, 
namely the multidrug resistance protein 3 (MDR3, ABCB4) [5]. The transport system for 
cholesterol at the canalicular membrane of hepatocytes is the protein heterodimer 
ABCG5/ABCG8 [7]. The efflux of lipids mediated by MDR3 and ABCG5/ABCG8 promotes 
the formation of mixed micelles containing bile acids, cholesterol, and phospholipids. This 
process not only solubilizes cholesterol, but also helps to protect cholangiocytes against the 
harmful detergent effects of  bile acids in the biliary tree.  
After their passage to the intestinal lumen, bile acids are efficiently taken up into 
ileocytes via the apical sodium-dependent bile acid transporter (ASBT, SLC10A2) [8]. 
Characteristic of the SLC10 family of transporters [9], ASBT contains seven transmembrane 
domains and its bile acid uptake activity is electrogenically coupled with cotransport of 
sodium. 
It has been proposed that transcellular shuttling of bile acids from the apical membrane 
domain of enterocytes to the basolateral membrane may be facilitated by the small cytosolic 
protein called the ileal bile acid-binding protein (I-BABP) [10,11]. It has been suggested that 
I-BABP physically interacts with ASBT [12], although the functional significance of this 
interaction remains unclear. 
At the basolateral membrane domain of ileal enterocytes, bile acids are extruded into 
portal blood by the heterodimeric organic solute transporter OST/OST [13]. The OST 
protein is predicted to contain seven membrane-spanning domains, whereas the smaller 
subunit OST has a single transmembrane domain. Coexpression of both OST and OST 
polypeptides is required for correct localization of the heterodimer at the cell membrane and 
for transport activity. Consistent with its role as the intestinal bile acid efflux transporter, 
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distribution of the OST/OST heterodimer along the intestine closely mirrors that of the bile 
acid uptake system ASBT. 
Finally, to complete the enterohepatic circulation, bile acids are extracted from the 
portal blood circulation by the liver. The sodium-taurocholate cotransporting polypeptide 
(NTCP, SLC10A1) at the sinusoidal membrane of hepatocytes is the chief uptake system for 
bile acids from portal blood into the parenchymal cells of the liver [14]. NTCP belongs to the 
same sodium-dependent SLC10 transporter family as ASBT, and is similarly likely to contain 
seven transmembrane domains and a cytoplasmic carboxy-terminus [9,15]. The amino acid 
identity between the human NTCP and ASBT is approximately 35 %. 
While NTCP is responsible for the sodium-dependent uptake of bile acids into 
hepatocytes, certain members of the organic anion transporter (OATP, SLCO) family, notably 
OATP1B1 (gene symbol SLCO1B1; previously known as OATP-C/OATP2/SLC21A6), may 
also contribute to bile acid extraction from the portal blood at the basolateral membrane of 
hepatocytes in a sodium-independent manner [16]. 
Under normal physiological conditions, only negligible amounts of bile acids are 
effluxed back to portal blood at the basolateral hepatocyte membrane. However, in cholestatic 
states, the expression of the two basolateral bile acid overflow systems of the ABC transporter 
family, multidrug resistance-associated proteins 3 (MRP3, ABCC3) and 4 (MRP4, ABCC4), is 
increased [17-19]. Thus, in cholestasis, MRP3 and MRP4 may transport substantial amounts 
of bile acids from hepatocytes back into the systemic circulation for subsequent renal 
excretion. In addition to MRP3 and MRP4, OST and OST are also expressed at the 
basolateral membranes of hepatocytes in humans [20]. It is thus conceivable that 
OST/OSTmay also contribute to alternative bile acid efflux during cholestasis. 
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Similarly to I-BABP in enterocytes, proteins that are putatively involved in 
intracellular trafficking of bile acids from the basolateral to the canalicular membrane have 
been identified in hepatocytes [21,22]. One such intracellular protein capable of binding bile 
acids with a high affinity in the human liver is the hepatic bile acid-binding protein (HBAB), 
which may thus assist in the rapid transcellular vectorial transport of bile acids in hepatocytes 
[23].  
 
9.3. Enterohepatic bile acid transporters in liver disease 
 
Chronic cholestatic liver diseases, such as primary biliary cirrhosis and primary sclerosing  
cholangitis, are characterized by an impairment of bile formation or of bile flow. Altered 
expression or function of bile acid transporters can be either a cause or a consequence of 
cholestasis, thus leading to hepatotoxicity due to accumulation of bile acids and cholephilic 
toxins in hepatocytes. Amongst the genes encoding transporters that are involved in bile acid 
transport or bile formation there are several that have been identified or proposed as disease 
genes in the pathogenesis of cholestasis. 
Progressive familial intrahepatic cholestasis, type 2 (PFIC2) is caused by mutations in 
the ABCB11 gene, which encodes BSEP [24,25]. These mutations in the ABCB11 gene lead to 
a rapidly progressive hepatic dysfunction in early infancy. In such patients the biliary bile salt 
levels can be reduced to less than 1 % of normal subjects. In a recent case report, specific 
ABCB11 mutations were identified in an adolescent cholestatic patient, which correlated with 
reduced BSEP protein expression in vivo and decreased bile acid transport activity in vitro 
[26]. Another case report suggested that heterozygous BSEP deficiency may predispose to 
transient neonatal cholestasis [27]. Furthermore, defective or altered function or expression of 
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BSEP may contribute to certain types of drug-induced cholestasis [28], and may be associated 
with intrahepatic cholestasis of pregnancy [29]. 
Defective MDR3 expression has also been associated with the inherited liver disease 
PFIC, namely the type 3 [30,31]. PFIC3 is characterized by high bile acid concentrations and 
elevated -glutamyl transpeptidase activity in serum. Several PFIC3-associated mutations in 
the ABCB4 gene may lead to either absent or severely decreased MDR3 expression at the 
canalicular membrane of hepatocytes. Similarly to BSEP, there is increasing evidence 
suggesting that deficiency of impaired activity of MDR3 may be involved in cholestasis 
induced by drugs, such as oral contraceptives [32,33]. 
Inherited mutations in the ABCC2 gene encoding the canalicular transporter MRP2 are 
linked to the Dubin-Johnson syndrome, characterized by reduced efflux of conjugated 
bilirubin into bile [34-37]. Some of these mutations have been reported to result in an absence 
of the MRP2 protein from the canalicular membrane of hepatocytes. In contrast to the PFIC 
syndromes, hepatic function is preserved in the Dubin-Johnson syndrome. 
Mutations in the SLC10A2 gene encoding ASBT have been identified that can cause 
primary bile acid malabsorption, a rare disorder of the intestine characterized by congenital 
diarrhoea, steatorrhea, and reduced plasma cholesterol levels [38]. The ASBT variants 
carrying these mutations exhibit severely reduced bile acid transport activity in vitro. 
No mutations in the SLC10A1 gene encoding NTCP leading to clinically manifest 
defects in hepatic bile acid uptake have been characterized thus far. However, a recent study 
identified ethnicity-dependent single nucleotide polymorphisms in the SLC10A1 gene that 
were associated with a considerable decrease in transport function in vitro [39] Thus, genetic 
heterogeneity in the SLC10A1 gene may play a role in the etiology of hypercholanemia. 
Furthermore, certain human diseases, such as advanced stage primary biliary cirrhosis [40] 
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and cholestatic alcoholic hepatitis [41], are associated with reduced NTCP expression. 
However, this change in NTCP expression may be a consequence of cholestatic liver injury, 
rather than a cause of it. 
 
9.4. Control of bile acid transport and metabolism 
 
In addition to their role as physiological detergents, bile acids possess crucial regulatory 
properties, which allow them to control their own transport and metabolism within the 
enterohepatic circulation through multiple feedforward and feedback mechanisms. 
Hepatocytes and enterocytes possess numerous signalling pathways that are activated or 
modulated by bile acids, and ultimately serve to maintain intracellular concentrations of 
potentially toxic bile acids at a constant level. 
An important mechanism towards controlling bile acid levels within cells is to adjust 
the cellular uptake or efflux of bile acids by regulating the expression and/or activity of 
uptake and efflux proteins, as will be discussed in detail below. It should be noted, however, 
that additional mechanisms are also operational in preventing intracellular bile acid 
concentrations from reaching toxic levels. One such mechanism is to regulate the de novo 
synthesis of bile acids according to the existing intracellular bile acid content. To reduce bile 
acid synthesis, the expression levels of the key CYP enzymes involved in de novo bile acid 
synthesis, namely CYP7A1, CYP8B1, and CYP27A1 are suppressed [42]. Furthermore, 
expression levels of several phase II enzymes that, in addition to their role in drug 
detoxification, may also convert bile acids into less toxic and more hydrophilic derivatives, 
are induced in response to elevated levels of bile acids [43]. These metabolizing enzymes 
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include uridine 5'-diphosphate-glucuronosyltransferase 2B4 (UGT2B4) and 
dehydroepiandrosterone sulfotransferase (SULT2A1).  
In this review we focus on the mechanisms that regulate the expression of bile acid 
transporters at the transcriptional level. However, it should be remembered that the activity of 
bile acid transporters is also known to be regulated at other levels, particularly through post-
translational protein modification and protein-protein interactions [44,45]. The relative 
importance of transcriptional and post-translational events in controlling bile acid transport 
activity in either normal physiology or pathophysiology remains largely unelucidated. Both 
are likely to be highly important. It seems likely that the mechanisms involving modification 
at the protein level could elicit the most rapid changes in transporter activity, whereas 
transcriptional changes may be responsible for more intermediate- and longer-term regulation 
of transport. 
 
9.5. Nuclear receptors as transcriptional regulators of bile acid homeostasis 
 
Nuclear and steroid receptors form a large family of transcriptional regulators, with over one 
hundred members in all metazoan organisms, and almost fifty members in humans [46]. Most 
nuclear/steroid receptors share a conserved overall structural design: a ligand-independent 
activation function at the amino-terminus, a central conserved DNA-binding domain, and a 
carboxy-terminal region containing regions mediating ligand-binding, dimerization, and 
ligand-dependent transactivation. Most nuclear/steroid receptors bind to their DNA response 
elements as either hetero- or homodimers, which is reflected in their preferred DNA-binding 
motifs typically containing two hexameric half sites. These hexamers, the general consensus 
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sequence for which is AGGTCA, can be arranged as direct (DR), inverted (IR), or everted 
(ER) repeats, separated by a variable and receptor-specific number of base pairs. 
The full transcriptional activity of most, but not all, nuclear/steroid receptors depends 
on a physical interaction by an agonist with their ligand-binding pocket. These ligands are 
typically small lipophilic molecules, such as hormones, fatty acids, oxysterols, or bile acids. 
Their binding induces a conformational shift in the carboxy-termini of the receptors, allowing 
their interaction with transcriptional coactivators [47]. These coactivators may act by 
modifying histones or other promoter-associated proteins, or by altering local chromatin 
structure, in a way that increases the rate of transcriptional initiation. Conversely, in the 
absence of an agonistic ligand, or when bound to an antagonistic ligand, the carboxy-termini 
of nuclear/steroid receptors associate with transcriptional corepressors that render the 
proximal promoters less permissive for transcription. The dependence of the transcriptional 
activity of most nuclear and steroid receptors on specific ligands allows them to monitor 
intracellular environment, and to elicit rapid transcriptional responses to changes in the 
concentrations of specific compounds.  
 
9.5.1. FXR - the master regulator of bile acid transport and metabolism 
 
The chief sensor of intracellular bile acid levels and the main executor of bile acid-induced 
transcriptional programmes is a nuclear receptor, namely the farnesoid X receptor (FXR) [48]. 
Bile acids directly interact with the ligand-binding domain of FXR. In transactivation and 
coactivator recruitment assays, CDCA is the most efficient FXR activator, followed by DCA 
and CA [49-51]. LCA alone can weakly activate FXR; however, it strongly antagonizes 
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CDCA-mediated stimulation of FXR [52]. This apparent antagonism of FXR function may 
contribute to LCA-induced cholestasis.  
Bile acids are not the only ligands that interact with FXR directly. Recently, it has 
been suggested that the oxysterol 22(R)-hydroxycholesterol, an intermediate in the synthesis 
of bile acids and steroid hormones, can also directly interact with the ligand-binding pocket of 
FXR and mediate gene activation [53]. Traditionally, oxysterols have been considered to be 
agonistic ligands for another member of the nuclear receptor family, the liver X receptor 
(LXR), which functions as a chief regulator of cholesterol homeostasis. Furthermore, 
androsterone, a testosterone metabolite, can directly interact with the FXR ligand-binding 
domain, and enhance transcriptional activity of FXR through coactivator recruitment [54]. It 
is possible that different ligands induce different conformational states of FXR, leading to 
distinct patterns of gene regulation [55]. In this review we only discuss the significance of bile 
acids as FXR ligands and activators of FXR-induced transcriptional programmes. 
In accordance with its function as a bile acid receptor, FXR is abundantly expressed in 
the  tissues exposed to bile acids: liver, intestine, and kidneys. The consensus DNA-binding 
motif for FXR is in the format of an inverted repeat-1 (IR-1, inverted hexameric repeat 
separated by one base pair) [56], to which it binds as a heterodimer with another nuclear 
receptor, the retinoid X receptor (RXR). However, other configurations, such as IR-0 and ER-
8, may allow binding of FXR in the context of specific promoters [57,58]. 
Supporting its physiological role in controlling bile acid homeostasis, FXR-null mice 
exhibit a phenotype similar to that of individuals suffering from Byler disease, an inherited 
cholestatic liver disorder [59]. Upon feeding with cholic acid, these mice lacking FXR exhibit 
severely increased hepatotoxicity, when compared to the wild-type counterparts. In further 
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support of the importance of FXR in human bile acid homeostasis, certain hereditary forms of 
cholestasis are associated with decreased FXR activity [60]. 
Encouraging reports showing hepatoprotective effects by synthetic FXR agonists in 
rodent models of cholestasis [61,62] suggest that specific FXR ligands could prove to be 
useful in the treatment of cholestatic liver diseases also in humans. One major concern 
regarding FXR-based therapy is that this nuclear receptor is involved in other metabolic 
processes in addition to bile acid homeostasis. Thus, its activation even with specific ligands 
may affect these unrelated processes in an undesired manner. For example, negative feedback 
suppression of bile acid synthesizing enzymes by bile acids is mediated by a complex cascade 
involving FXR, leading to reduced conversion of cholesterol to bile acids. In addition to 
controlling bile acid transporter and synthesis genes, FXR is crucially involved in glucose 
homeostasis via regulation of the genes encoding gluconeogenic enzymes [63,64]. In addition, 
FXR activated by bile acids has been recently shown to be an important mediator of liver 
regeneration [65]. It was hypothesized that FXR activation by increased level of bile acids 
would be a signal of reduced hepatic capacity and function. Thus, until the liver reaches the 
sufficient number of new hepatocytes to cope with the bile acid levels, FXR continues to 
trigger their proliferation.  
 
9.5.2. The role of PXR and VDR as bile acid sensors 
 
FXR is not the only nuclear receptor that can use bile acids as ligands that modulate 
transcriptional activity. In addition, the pregnane X receptor (PXR) and the vitamin D 
receptor (VDR) can mediate transcriptional responses to certain bile acids. PXR, together 
with its xenosensor partner constitutive androstane receptor (CAR), is a nuclear receptor that 
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typically utilizes drugs and xenobiotics as its ligands [66]. In response to these ligands, PXR 
induces the expression of genes encoding proteins involved in drug detoxification and 
elimination pathways. In addition to xenobiotics, certain bile acids, such as the highly toxic 
LCA, can serve as agonistic ligands for PXR [67,68]. Indeed, activation of PXR can protect 
mouse livers against LCA-mediated injury [67]. Double knock-out mice lacking both FXR 
and PXR exhibit more severe disturbances of bile acid metabolism than mice lacking only one 
of the nuclear receptors, demonstrating that both contribute to bile acid homeostasis [69]. 
PXR is a master regulator of the gene encoding the CYP3A4 enzyme [70], which, in addition 
to its role in detoxifying xenobiotics, also metabolizes bile acids to less toxic and more easily 
excreted derivatives. Thus, by being both activators of the CYP3A4 gene and substrates of the 
CYP3A4 enzyme, bile acids can initiate a hepatoprotective feedforward loop via PXR. 
Similarly to PXR, VDR can utilize the toxic secondary bile acid LCA as an agonistic ligand 
[71]. While VDR is only weakly expressed in hepatocytes, it is abundantly present in 
enterocytes. It is thus likely to play a more prominent role in the intestine in response to LCA. 
In addition to PXR, VDR can also transactivate the CYP3A4 gene. Thus, VDR activated by 
elevated levels of LCA in the intestine may, in a feedforward manner, contribute to enhanced 
expression of the CYP3A4 enzyme, which is capable of detoxifying LCA. 
Common to all three nuclear receptors, FXR, PXR, VDR, that can utilize bile acids as 
ligands, is that they all bind to their respective DNA response elements as heterodimers with 
the nuclear receptor RXR, with very few exceptions. Positive or negative effects on the 
transcriptional activity of RXR-containing heterodimers by the RXR ligand 9-cis-retinoic acid 
appear to depend on the exact promoter context [72,73]. 
 
9.5.3. The bile acid-induced transcriptional repressor SHP 
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FXR can also negatively regulate the rate of transcription from specific promoters. In rare 
cases, FXR is known to repress its target genes, such as those encoding the human 
apolipoprotein A-I  [74] and human apolipoprotein C-III [75], through direct binding to the 
promoter. However, FXR more commonly mediates negative transcriptional responses to 
elevated levels of bile acids indirectly, through inducing the expression of its target gene 
encoding the transcriptional repressor called small heterodimer partner, SHP. SHP is an 
atypical member of the nuclear receptor family: it does not contain a DNA-binding domain, 
and does not depend on a ligand for its activity. Instead, it directly interacts with a variety of 
DNA-bound transcriptional activators, interfering with their transcriptional activity. While 
SHP can suppress the activity of transcription factors from certain other families, it most 
commonly targets other nuclear receptors and steroid receptors (reviewed in [76]). Via the 
SHP pathway bile acids can influence the activities of a wider range of transcription factors 
than only those nuclear receptors that are directly modulated by them. 
Several mechanisms have been suggested for SHP-mediated suppression of 
transactivator proteins. SHP may compete with transcriptional coactivators over the same or 
overlapping interaction surface on transactivators that are bound to the promoter elements 
[77]. Alternatively, SHP may interfere with the binding of transactivators  to their DNA 
response elements [78]. Additionally, SHP may recruit transcriptional corepressors to its 
target promoters, thus contributing to the reduced transcriptional rate of a given promoter 
[79]. 
The importance of SHP in the control of bile acid homeostasis is indicated by the fact 
that SHP-null mice exhibit an imbalance in bile acid metabolism and abnormal responses 
when challenged with diets rich in bile acids [80,81]. 
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9.6. FXR-dependent mechanisms that regulate human bile acid transporter genes 
 
We will next discuss the FXR-dependent effects of bile acids on the expression of transporter 
genes in hepatocytes and enterocytes. These concepts are summarized in Figure 9-2. 
It should be emphasized that while we focus on FXR-dependent effects by bile acids 
in this review, bile acids do also elicit signalling pathways that lead to changes in specific 
gene expression, which are independent of FXR or other nuclear receptors. These alternative 
bile acid-stimulated pathways include signalling through mitogen-activated protein kinases 
[82,83] and through the G-protein-coupled receptor TGR5 [84]. Parallel bile acid-stimulated 
signalling pathways may ensure that the desired transcriptional responses are achieved. 
 
9.6.1. Positive feedforward control of bile acid efflux systems by bile acids 
 
In response to bile acids FXR induces BSEP expression via direct interaction of FXR-RXR 
heterodimers with an IR-1 element located in the proximal promoter of the ABCB11 gene [85-
87]. Thus, excessive levels of bile acids stimulate hepatocanalicular clearance of bile acids. 
The FXR-RXR binding element is conserved between the human and rodent ABCB11/Abcb11 
promoters, supporting its functional importance. In agreement with FXR being a crucial 
activator of the ABCB11 gene, the BSEP expression is reduced in mice lacking the FXR gene 
[59].  
The ABCC2 gene encoding the MRP2 transporter provides an illustrative example of 
the complex interactions between the metabolic nuclear receptors. Both the human and rodent 
ABCC2/Abcc2 promoters can be activated by either FXR, PXR, or CAR in the presence of 
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their respective ligands or activators [58]. Interestingly, each of these three nuclear receptors 
can interact with the same atypical ER-8 element present in the regulatory region of the 
ABCC2 gene. The relative significance or the degree of redundancy between the three 
transcription factors in the regulation of MRP2 expression is not yet clear. 
FXR also transactivates the ABCB4 gene encoding MDR3, the phospholipid 
transporter at the canalicular membrane of hepatocytes [85]. Thus, bile acids may, in a 
coordinated manner and via activation of FXR, induce the excretion of both bile acids (BSEP, 
MRP2) and phospholipids (MDR3) into bile. In agreement with this, FXR-null mice are prone 
to developing cholesterol gallstones, caused by the deficiency in the excretion of bile acids 
and phospholipids [59]. 
Expression of the genes encoding the alternative bile acid export pumps at the 
basolateral hepatocyte membranes, MRP3 (ABCC3) and MRP4 (ABCC4), appears to be 
induced in cholestasis in an FXR-independent manner, at least in bile duct-ligated or bile 
acid-fed mice [86,87]. It may be that the other bile acid-responsive nuclear receptor PXR is 
responsible for the bile acid-mediated induction of the ABCC3 and ABCC4 genes, or can at 
least compensate in the absence of FXR [88]. In agreement with the cholestatic mouse 
models, it has been reported that in human cholestatic liver disease, expression of MRP3 and 
MRP4 is similarly elevated [40,89,90]. 
In analogy to the ABCB11 gene encoding the hepatic efflux system BSEP, the two 
genes encoding the heterodimeric efflux system in the intestine, OST/OST are induced by 
bile acids through direct binding of FXR-RXR heterodimers to the two human OST promoters 
[91,92]. While the OST promoter appears to have a single IR-1-like binding site for FXR-
RXR, the human OST promoter contains two adjacent IR-1-like FXR response elements, 
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both of which are functional and required for full response to bile acids. Physiological 
evidence in support of the induction of OST expression by bile acids is provided by a recent 
study showing that both mRNA and protein levels of OSTand OST are increased in 
cholestatic liver tissue of primary biliary cirrhosis patients [93]. In further agreement with the 
proposed role of FXR in inducing the OST genes, their baseline expression is reduced and 
their bile acid-mediated induction is abolished in FXR-null mice [92-94]. Accordingly, the 
location and sequence of the IR-1-like FXR response elements are largely conserved in both 
human and mouse OST and OST genes. 
Bile acid-activated FXR also stimulates expression of the gene encoding the 
intracellular bile acid transporter I-BABP in the ileum [95]. Supporting this, I-BABP 
expression is dramatically reduced in FXR-deficient mice [59]. FXR response elements of the 
IR-1 type have been identified in both the human and rodent I-BABP/I-babp promoters. The 
bile acid-activated FXR can thus upregulate the expression of both the membrane-bound bile 
acid uptake system OST/OST and the intracellular bile acid transporter I-BABP in a 
coordinated manner within enterocytes. 
 
9.6.2. Negative feedback control of bile acid uptake systems by bile acids 
 
In rodent models of cholestasis, such as bile duct ligation or bile acid feeding, expression of 
the hepatic bile acid uptake system Ntcp is suppressed at both the protein and mRNA level 
[96,97]. Furthermore, certain human cholestatic states, such as advanced stage primary biliary 
cirrhosis [40] and cholestatic alcoholic hepatitis [41], are similarly associated with reduced 
NTCP expression. It has been recently suggested that the mechanism of down-regulation of 
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human NTCP expression in response to bile acids involves the FXR-SHP cascade. FXR-
induced SHP targets the transactivator glucocorticoid receptor (GR), which interacts with its 
response element just upstream of the transcription initiation site on the human SLC10A1 
promoter [98]. 
FXR also suppresses transcription of the SLCO1B1 gene encoding the sodium-
independent bile acid transporter OATP1B1 at the basolateral membrane of human 
hepatocytes [99]. FXR-mediated repression of the SLCO1B1 promoter takes place through a 
multistep regulatory cascade, which involves bile acid-mediated repression of the gene 
encoding the liver-enriched homeodomain factor hepatocyte nuclear factor-1 (HNF-1). 
HNF-1, in turn, is a strong DNA-binding transactivator of the OATP1B1 promoter. The 
regulatory region of the HNF-1 gene contains a consensus DNA-binding response element 
for the nuclear receptor HNF-, the transcriptional activity of which can be targeted by 
negative interference by FXR-induced SHP.  
Similarly to NTCP, treatment of cultured cells with bile acids suppresses the 
expression of the intestinal bile acid uptake transporter ASBT, another member of the SLC10 
transporter family in humans [100]. In accordance with this, SLC10A2 gene expression is 
reduced in patients with obstructive cholestasis, when compared to healthy controls [101]. 
Two transactivators of the human SLC10A2 promoter, namely the GR [98,102] and the 
nuclear receptor heterodimer, retinoic acid receptor (RAR)-RXR [100], have been suggested 
as targets for negative interference by the bile acid-induced transcriptional repressor SHP. It 
remains to be determined whether these two transactivators are simultaneously targeted by 
SHP to ensure efficient downregulation of the SLC10A2 promoter by bile acids, or whether 
the two pathways are targeted under different circumstances. Interestingly, while both the 
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SLC10A1 (NTCP) and SLC10A2 (ASBT) genes are transactivated by GR, the relative 
locations and configurations of the GR response elements within the two promoters are not 
conserved. 
 
9.7. Crosstalk between the transcriptional control of bile acid and drug transporters 
 
Transport and metabolism of exogenous compounds, such as drugs, nutrients, and 
environmental xenobiotics, bear many similarities to those of endogenous bile acids. Indeed, 
drugs may undergo enterohepatic circulation similarly to bile acids. Several transporters 
recognize both bile acids and drugs as substrates. For example, although their significance for 
overall bile acid transport in normal physiology remains uncertain, the two transporters of the 
human OATP1B subfamily, OATP1B1 and OATP1B3, can transport bile acids, in addition to 
drugs such as methotrexate and rifampicin [103]. The transcriptional regulatory circuits 
controlling the expression of drug transporter genes often contain feedforward and feedback 
loops, reminiscent of the mechanisms outlined for regulation of bile acid transport above 
(reviewed in [76]). It is becoming increasingly apparent that, in addition to reprogramming of 
genes involved in bile acid homeostasis, changes in intracellular concentrations of bile acids 
also influence the expression levels of hepatic and intestinal drug transporters. Thus, changes 
in intracellular bile acid levels may affect the efficiency of drug extraction and elimination. 
HNF-4 is a liver-enriched nuclear receptor with a critical role in maintaining the 
hepatic pattern of gene expression [104]. It binds to the DNA response elements on its target 
promoters, preferably of the DR-1 or DR-2 configuration, as homodimers. The ligand-binding 
domain of HNF-4 has been suggested to be constitutively bound by endogenous fatty acids 
[105,106], thus its activity may not be readily modulated by exogenous ligands. In addition to 
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its previous roles in regulation of glucose and cholesterol metabolism, HNF-4 has recently 
emerged as a regulator of hepatic drug transport in humans. The genes encoding two major 
hepatic basolateral drug transporters in humans, namely organic anion transporter 2 (OAT2; 
SLC22A7) [107] and organic cation transporter 1 (OCT1; SLC22A1) [108], are transactivated 
by HNF-4. OAT2 mediates uptake of drugs such as salicylates and cephalosporins from 
sinusoidal blood, whereas OCT1 transports dopamine, metformin, and verapamil, amongst 
other substrates. 
In the regulatory regions of the human SLC22A7 gene, HNF-4-mediated 
transactivation is mediated by a single DR-1 element. The human SLC22A1 promoter, in turn, 
contains two adjacent lower-affinity DR-2 elements, both of which are required for maximal 
transactivation by HNF-4.In both promoter contexts, the bile acid-induced transcriptional 
repressor SHP interferes with transactivation by HNF-4. It thus appears that in conditions of 
elevated intracellular bile acid concentrations, the expression of two major drug uptake 
systems at the basolateral hepatic membrane is reduced. This could limit the amount of 
xenobiotics that enter the hepatocyte for subsequent metabolism, when intracellular levels of 
toxic bile acids are already elevated. Also, the possibility of decreased hepatic extraction of 
drugs that are substrates of OAT2 and OCT1 should be taken into account, when such drugs 
are administered to patients suffering from cholestasis. 
 
9.8. Concluding remarks 
 
Enterohepatic bile acid transporters are crucial in maintaining bile acid homeostasis in healthy 
individuals. Their importance for hepatic and intestinal function is emphasized by numerous 
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recent demonstrations that either hereditary or acquired disturbances in the activity and/or 
expression of bile acid transporters are associated with cholestatic disease conditions. Bile 
acids regulate the expression of transporters that mediate the enterohepatic circulation of both 
bile acids and drugs via complex feedforward and feedback mechanisms. The main 
orchestrator of these transcriptional circuits is FXR, which, in response to bile acids, controls 
the expression levels of bile acid transporters at all membrane domains of enterohepatic 
circulation.  
Increased knowledge of the transcriptional mechanisms governing the changes in bile 
acid transporter gene expression has progressed our understanding of the pathophysiology of 
cholestatic liver diseases. Additionally, this information is likely to provide us with novel 
tools for designing therapeutic strategies to combat diseases of the liver and the intestine. 
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